⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 2, 2017BMJ

Conditional approval of medicines by the EMA

Rita Banzi Chiara Gerardi Vittorio Bertelè Silvio Garattini

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

The process fails to improve the evidence after early licensing

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Banzi et al. (2017) studied this question.

synapsesocial.com/papers/6a8847d8d03e68c3c9a54a6f https://doi.org/10.1136/bmj.j2062

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Extreme weather events: A practical guide for cliniciansBMJ · Fri,
2Loneliness at work: We need to restore connectedness for resident doctorsBMJ · Fri,
3Heatwaves linked with 50 000 deaths in Europe’s urban areas this summer, with climate change responsible for two thirdsBMJ · Fri,
4Global security crisis and COP31: a duty to accelerate phasing out fossil fuelsBMJ · Thu,
5Water shortages: how can hospitals prepare and are water companies doing enough?BMJ · Thu,

More from BMJ

Conflict and climate are compounding challenges for women’s and children’s healthWed,
Acetic acid chromoendoscopy for detection of neoplastic Barrett’s oesophagus: stepped wedge cluster randomised controlled trial (ACID-trial)Wed,
Green transition provides a crucial opportunity to finance universal health coverageWed,
In South Asia the most vulnerable people are paying for a climate crisis created by high income countriesWed,
Effectiveness of a structured template to improve completeness of reporting randomised trial protocols: randomised controlled trialTue,